Among Swedish memory-clinic patients without dementia, more stressful life events were linked to a spinal-fluid sign of Alzheimer’s amyloid buildup, but only in people with moderate-to-high insomnia symptoms, according to a 2026 study.1 Research Highlights Stress and insomnia worked together: in 103 patients with spinal-fluid tests, lifetime stressful events and insomnia symptoms interacted in relation …
A 2026 PROTECT study involving 174 older adults found that self-administered fingerprick p-tau217 correlated with episodic memory (r = 0.299, p < 0.001) and GFAP correlated with working memory (r = 0.183, p = 0.034), supporting remote Alzheimer's risk triage rather than a stand-alone dementia diagnosis. Research Highlights Fingerprick sampling reached 77% completion: 174 of …
A 2026 Nature Aging study involving 520 participants found that plasma protein-structure signatures classified healthy control, mild cognitive impairment, and Alzheimer’s disease groups with 83.44% three-way accuracy.1 The result is a serious biomarker signal, but it is not a clinic-ready replacement for established Alzheimer’s testing. Research Highlights Classification was strong: The plasma structural-proteomics panel reached …
A 2026 PLOS One computational study linked Trichostatin A to 949 predicted targets and 8 machine-learning-selected Alzheimer’s disease core genes, but 100 ns molecular dynamics simulations suggested the compound did not stably bind those candidate proteins.1 That makes the result more useful as an epigenetic network hypothesis than as evidence for a near-term Alzheimer’s drug. …
A 2022 Nature Communications study used non-contrast 3D T2-FLAIR magnetic resonance imaging (MRI) to map human brain lymphatic signals in living people, including apparent channels from cranial nerves and skull-base structures toward cervical lymph nodes. Research Highlights Non-contrast MRI visualized lymphatic-like brain drainage: Albayram et al. identified dorsal dural signals near venous sinuses and ventral …
A 2026 Molecular Psychiatry study found that oral FP802 disrupted the NMDAR/TRPM4 death complex and preserved memory-task performance in 5xFAD Alzheimer’s mice treated for 3 months.1 The finding is mechanistically sharper than a generic anti-amyloid claim: FP802 targeted a glutamate-toxicity complex downstream of amyloid stress. Research Highlights Complex formation was blocked: 5xFAD mice had increased …
In APP/PS1 Alzheimer's model mice, deleting PTP1B or treating with the allosteric inhibitor DPM-1003 improved memory behavior, lowered amyloid burden, and pushed microglia toward SYK-driven clearance — a plausible mechanism, not a human treatment result yet.1 Research Highlights PTP1B loss improved behavior in APP/PS1 mice. Genetic deletion and DPM-1003 treatment improved novel object recognition and …